Suppr超能文献

[普罗帕酮用于老年患者室性期前收缩。耐受性与疗效]

[Propafenone in ventricular extrasystole in elderly patients. Tolerance and efficacy].

作者信息

Camous J P, Benoit P, Vrancea F, Gibelin P, Schenowitz A, Baudouy M, Varenne A, Morand P

出版信息

Ann Cardiol Angeiol (Paris). 1987 Apr;36(4):179-82.

PMID:2438971
Abstract

The tolerance and efficacy of propafenone were studied in cases of chronic ventricular extrasystoles of the elderly (age greater than 70 years). Only patients presenting more than 1,000 extrasystoles per day and requiring a treatment, were included in this study. Patients presenting non-compensated cardiac insufficiency, hypotensive patients, patients with conduction disorders without pacemakers as well as patients presenting a severe renal or hepatic insufficiency, were excluded. After making sure that the rhythm disorder was chronic, a control Holter was performed, then, 600 mg of propafenone per day, in 3 doses were prescribed for 5 days. On the 5th day, a Holter was performed as well as a blood propafenone level. Some patients received then 900 mg per day with a new Holter and plasma propafenone titration on the 10th day. 11 patients were studied in this fashion. The tolerance to 600 mg was good in 10 out of 11 cases. The efficacy, appreciated by the decrease of the number of isolated ventricular extrasystoles (-69%), doublets (-95%), triplets (-98%) and salvos of ventricular tachycardias (-100%), was excellent in 6 cases, average in 2 cases and mediocre in 3 cases. Increase of the dosage to 900 mg does not improve significantly the anti-arrhythmic efficacy while the side effects seem more frequent. It is not possible to establish a relationship between plasma concentrations and efficacy. At a dosage of 600 mg per day, propafenone is therefore effective in the treatment of ventricular extrasystoles in elderly patients and its tolerance is good. Higher doses are not advisable as they seem much less well tolerated without any additional advantage.

摘要

研究了普罗帕酮在老年慢性室性早搏患者(年龄大于70岁)中的耐受性和疗效。本研究仅纳入每天早搏超过1000次且需要治疗的患者。排除存在失代偿性心功能不全的患者、低血压患者、无起搏器的传导障碍患者以及严重肾或肝功能不全的患者。在确定心律失常为慢性后,进行一次动态心电图检查,然后每天给予600mg普罗帕酮,分3次服用,共5天。在第5天,进行一次动态心电图检查并检测普罗帕酮血药浓度。部分患者随后每天服用900mg,并在第10天进行一次新的动态心电图检查和普罗帕酮血药浓度测定。以这种方式研究了11例患者。11例中有10例对600mg的耐受性良好。根据孤立性室性早搏数量减少(-69%)、成对早搏(-95%)、三联律(-98%)和室性心动过速连发次数减少(-100%)评估疗效,6例疗效极佳,2例疗效中等,3例疗效一般。将剂量增加至900mg并不能显著提高抗心律失常疗效,而副作用似乎更频繁。无法确定血药浓度与疗效之间的关系。因此,每天600mg的剂量对老年患者室性早搏有效且耐受性良好。不建议使用更高剂量,因为它们的耐受性似乎差得多且没有任何额外优势。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验